Tacere Therapeutics
Benitec Biopharma hit two key milestones recently in its effort to advance its expressed RNAi-based hepatitis C treatment TT-034 into the clinic, securing a commitment to sell A$7 million ($6.7 million) of its stock to new and existing shareholders and receiving a favorable revie
Shares of Benitec Biopharma resumed trading on the Australian Stock Exchange this week after the company announced that it had closed a A$800,000 ($821,760) private placement that it said would give it resources enough to fund a clinical trial of its recently reacquired hepatitis
Two years after the US Patent and Trademark Office reinstated its core patent, Australia's Benitec Biopharma has once again set its sights on finding licensees for its expressed RNAi intellectual property.
Benitec Biopharma last week said that it has completed its acquisition of Tacere Therapeutics, which was first announced last month.
With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.
Oct 11, 2012
Oct 11, 2012
Jun 21, 2012
Feb 10, 2011
Dec 23, 2010
Dec 16, 2010
Dec 9, 2010
Nov 4, 2010
Jul 22, 2010
Feb 11, 2010
Sep 17, 2009
Aug 20, 2009